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The Laboratory of Pharmacology initiates and
carries out research programs that are primarily
concerned with (1) mechanisms by which environ-
mental pollutants and effectors cause toxicity, (2)
the development ofbetter test systems for detecting
and evaluating early toxic effects of chemicals oc-
curring as environmental contaminants, and (3) ex-
trapolating from animal test systems across species
and to man. The Laboratory is organized into three
formal sections and one work group. The sections
are Toxication-Detoxication, Marine Pharmacol-
ogy and Biomedicine, and Pharmacokinetics; the
work group is Molecular Pharmacology and
Biomedicine.
Program
Toxication-Detoxication Section
This program area is concerned with the role of
chemical metabolism in the production of tissue
damage and toxicity. Metabolism leading to in-
creased toxicity may be balanced by reactions with
detoxifying systems. This balance between toxica-
tion and detoxication pathways may be altered by
pollutants, other chemicals, pathologic states,
physiological changes (age or pregnancy), species
and strain differences, hormonal changes, or it may
be different in one tissue from another. Chemical-
metabolizing systems have been or are being
characterized in tissues most likely to contact the
environment, i.e., skin, intestine, lung, and liver, as
well as in steroidogenic tissues containing germinal
cells (ovary, testis). Characterization includes sub-
strate and inhibitor specificity, ability to be acti-
vated, induced, or inhibited by exposure to other
chemicals and changes in physiological status (e.g.,
pregnancy), and measurement and purification of
multicomponent systems or enzyme families (e.g.,
cytochrome P-450-dependent mixed-function ox-
idase [MFO] systems or the glutathione
S-transferases).
Two different forms of cytochrome: P-450 (ab-
sorption maxima ofreduced-CO bound cytochrome
occurred at 425.5 nm and 450 nm, respectively)
were separated from the same rabbit lung mi-
crosomal preparation. The lipid requirement for
maximal MFO activity is being studied in reconsti-
tuted systems. Cytochrome P-448 was purified
from livers of control and 3-methylcholanthrene-
pretreated rabbits; the cytochromes were identical
based on purification procedures, monomeric
molecular weight, and immunological tests.
Techniques are being developed to separate and
culture lung cells for studying chemical toxication
and detoxication mechanisms at the cellular level.
Mammalian skin has very low, but detectable,
MFO activity. In mice, at least, this activity seems
to be increased following exposure to shortwave
ultraviolet irradiation (254 nm) or to a sunlamp
-conditions that might mimic prolonged exposure
to sunlight.
The effects ofpretreating mice, rats, guinea pigs,
and rabbits, with known inducers of hepatic MFO
activity, on intestinal xenobiotic-metabolizing en-
zyme activities were studied. The induction of in-
testinal MFO enzymes varied with the animal
species and the xenobiotic used as substrate, which
is consistent with the idea that chemically induced
toxicity in this tissue may be partially dependent on
species.
The formation and subsequent biotransformation
of chemically reactive alkene and arene oxides,
formed from alkenes and polycyclic aromatic com-
pounds, are being studied in liver and several ex-
trahepatic tissues of rats and rabbits. Comparative
studies utilize partially purified enzymes, subcellu-
larfractions oftissue homogenates and isolated per-
fused lung, liver, and testis preparations. The rela-
tive importance of glutathione S-transferase and
epoxide hydrase activities in the metabolism and
detoxication of chemically different epoxides is
being assessed. Substrate specificities with differ-
ent synthetic oxides that are thought to be car-
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pre-exposure of animals to other xenobiotics, to
depiction ofrequired endogenous cofactors, and to
normal physiological control mechanisms on en-
zyme activities and epoxide-induced toxicity is also
determined.
All of the studies in this section seek to under-
stand the relationships between xenobiotic
metabolism and the localized toxicity (i.e., target
organ), both acute and chronic, caused by exposure
to environmental pollutants.
Marine Pharmacology and Biomedicine
This program area conducts studies on uptake,
distribution, metabolism, and excretion of pollu-
tants by various marine species, the role of
metabolism of these pollutants in their storage and
the chemical moiety stored in these species, and the
use ofmarine organisms to identify those physiolog-
ical processes that are especially sensitive to ex-
posure to certain xenobiotics (e.g., organochlo-
rines).
One area of major emphasis is the potential ac-
cumulation of carcinogens, mutagens, teratogens,
cytotoxins, and marine toxins (i.e., chemicals that
may be particularly dangerous to mail) in aquatic
species. The effect of exposure to pollutant mix-
tures on accumulation ofchemicals is also studied.
Operation of a year-round facility (the C. V.
Whitney Marine Laboratory, University ofFlorida,
St. Augustine) allows investigations which expand
and complement our seasonal (summer) studies at
Mount Desert Island Biological Laboratory,
Maine. Comparisons are being made ofthe effect of
environmental temperature on metabolic, excre-
tory, and storage processes for pollutants. Cur-
rently, the disposition of aliphatic and aromatic
constituents ofcrude and refined oils is underinves-
tigation.
The biotransformation of various organic pollu-
tants is studied in hepatic and extrahepatic tissues of
vertebrate and invertebrate marine species from
coastal Maine and Florida. Particular emphasis is
placed on studying formation and further
metabolism of chemically reactive electrophilic
metabolites. Both cytochrome P-450-dependent
microsomal mixed-function oxidases and alkene- or
arene oxide-metabolizing enzymes (epoxide hy-
drase and glutathione S-transferases) are being
characterized in control marine species and in
species pre-exposed to environmental contaminants
such as the polycyclic aromatic hydrocarbons.
Where biologically significant induction is ob-
served, the induced system isbeing characterized in
considerable detail, e.g., in little skates, where
cytochrome P-448 has been identified for the first
time in an aquatic animal.
The pharmacokinetics ofpollutant distribution in
selected marine species is being determined and
compared with mammals (in collaboration with the
Pharmacokinetics Section). So far we have shown
that a polychlorinated biphenyl (PCB) isomer is
stored in different tissues in different marine
species and that the biological half-life of PCB cor-
relates with the ability of the species to metabolize
it. Compared with mammalian systems, marine
species have a relative deficit in the capability to
carry out oxidative chemical metabolisms, while
possessing adequate levels ofenzymes for conjuga-
tion reactions. Thus, we have shown that water-
soluble pollutants, such as 2,4-D and 2,4,5-T, are
rapidly conjugated with amino acids and excreted in
the bile and urine of teleosts and elasmobranchs.
Other areas being investigated include the impor-
tance of renal and hepatic organic anion transport
systems in elimination ofxenobiotic metabolites by
marine species, the role ofintracellular binding pro-
teins (the glutathione S-transferases) in cellular
transport and toxicity of organic anions, and the
role of membrane function in relationship to target
organ accumulation ofxenobiotics or their metabo-
lites and toxicity. Emphasis is placed on correlating
in vitro biochemical and physiological measure-
ments with in vivo function (e.g., osmoregulation).
Since many endogenous compounds utilize active
transport systems in various tissues of the body,
these studies also attempt to elucidate interactions
between xenobiotic metabolites and endogenous
molecules utilizingthe same transportmechanisms.
The Section is also involved in developing a na-
tional program in marine pharmacology and
biomedicine as directly applicable to human health
problems (models for human disease, sources of
toxic materials for man). The main direct concern
to the NIEHS will be to provide afocus for DHEW
activities in marine biomedical studies.
Molecular Pharmacology and
Biochemistry Work Group
This group is involved in studies which can be
categorized as pharmacological and biochemical re-
search on synthesis, metabolism, release, isolation,
and identification of endogenous chemicals (lipids,
proteins, enzymes) involved in lung function, both
in normal and in disease states. Information is being
used to develop markers for early human disease
states of possible environmental origin.
One group is concerned with the identification
and characterization of components which are lung
specific or pulmonary disease-related which could
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age or disease. Current attention is being focused
on: (1) the soluble alkaline phosphatases of the
normal lung, (2) abnormal hydrolases present in
pulmonary lavage effluents from patients with al-
veolar proteinosis, and (3) enzymic components of
human amniotic fluid which originate in the fetal
lung.
Human lung was found to contain two distinct
alkaline phosphatases having molecular weights of
213,000 and 125,000 daltons. These enzymes appear
to be lung-specific with the lower molecular weight
form present in extracellular lining ofairways. This
work was done in collaboration with Duke Univer-
sity and George Washington University. Further
studies have characterized the high molecular
weight (> 20 x 106 daltons) soluble alkaline phos-
phatase (AP) complex found in pulmonary lavage
effluents ofpatients with alveolar proteinosis, a dis-
ease of suspected environmental etiology. After
appropriate chemical treatment of the complex, a
low molecular weight AP is released which appears
similar to the AP's found in normal lung.
Another group of investigators is focusing on the
potential of normal and neoplastic cells of the lung
to synthesize polypeptide hormones. A pituitary-
like cell has been identified in the lungs of several
species and designated P cell. These cells may be
target progenitors for lung tumors, such as oat cell
carcinoma, which are capable of producing bioac-
tive polypeptide hormones. Four mammalian
squamous cell carcinomas were found to contain
immunoreactive adrenocorticotropic hormone
(ACTH) and this immunoreactivity was associated
with "big ACTH" rather than "small ACTH."
"Big ACTH" was also found in the extract of
bovine pituitary gland.
Since human bronchogenic squamous cell car-
cinomas are known to produce a large form of
ACTH, an investigation has been initiated to purify
this material from bovine pituitary glands so that a
specific radioimmunoassay might be developed.
Hypersecretion of cell-specific or tumor-specific
polypeptides or proteins could serve as a means for
sensitive detection of pulmonary neoplasia or pre-
neoplasia.
A third group of investigators is studying the
biosynthesis, release, and metabolism of prostag-
landins (PG) and thromboxanes (TX) in pulmonary
tissue. A transport system responsible for removing
PG from the circulation into the lung was observed
and characterized by the group. The structural re-
quirement necessary for transport was examined
using the isolated perfused rat lung. Some chemi-
cals and anti-inflammatory agents inhibited the
transport system. Exposure of rats to pollutants
(02, NO2) inhibited the pulmonary metabolism of
PG but did effect the transport system. The major
metabolites of PG, 15-keto PG were found to be
further metabolized by glutathione S-transferase to
the corresponding glutathione conjugate.
PG and TX biosynthesis were studied. During
the formation of PG and TX, a metabolite(s) of
arachidonic acid (AA), the precursor substance for
PG, was covalently bound to tissue protein. Since
AA or the known end-products, PG and TX, did
not react with tissue, reactive intermediates were
probably formed which reacted with tissue. The na-
ture of the reactive intermediate is currently under
investigation. The covalent binding of these en-
dogenous chemicals may be associated with or be
responsible for pulmonary toxicity induced by en-
vironmental agents. Irritation of pulmonary tissue
by exposure to pollutants initiates the biosynthesis
and release of PG and TX. Covalent binding ofAA
metabolites was found in other tissues including
platelets, seminal vesicles, kidney, and stomach.
These investigators also studied the co-oxy-
genation of chemicals during the formation of
PG and TX. During this formation in guinea pig
lung, benzpyrene (BP) was oxidized to metabolites
which appeared to be quinones with little or no for-
mation of monohydroxy- and dihydrodiol metabo-
lites, but in the presence of NADPH, the major
benzpyrene metabolite was dihydrodiol. Approxi-
mately 20% ofthe BP oxidized during the formation
of PG was covalently bound to protein while only
5-8% of the metabolites formed in the presence of
NADPH was bound to protein.
Activation ofbenzpyrene during the formation of
PG and TX may be related to the induction of pul-
monary carcinogenesis and may represent an alter-
nate mechanism to oxidation of chemicals by the
cytochrome P-450 system.
Pharmacokinetics Section
This section is conducting research in at least two
majorcategories: (1) whole body distribution ofpol-
lutants and formulation ofpharmacokinetic models
for extrapolation, and (2) uptake, storage, me-
tabolism, and release of pollutants and model
compounds by isolated perfused organs, with pres-
ent emphasis on lung and liver. The kinetics of
chemical disposition in intact animals and isolated
organs are being determined in order to construct
mathematical models of these processes which can
be used to better define and understand rate-
limiting steps in the process, toextrapolate distribu-
tion profiles of chemicals from one tissue to
another, one species to another and to man, and to
predict tissue storage ofpollutants from knowledge
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parisons of the kinetics of pollutant distribution in
mammalian vs. marine species are being carried out
in collaboration with Marine Pharmacology and
Biomedicine, as previously mentioned.
Through extensive collaboration with the Bio-
medical Engineering and Instrumentation Branch,
DRS, NIH (Drs. R. L. Dedrick and R. Lutz),
pharmacokinetic models have been developed for
four PCB isomers in the rat. The biochemical and
physiological parameters used in these models were
determined from studies in bile-cannulated animals,
isolated perfused liver studies, and whole animal
disposition studies.
These models can predict the disposition of the
PCBs after a single intravenous or oral dose. Re-
cently the models have successfully predicted the
disposition of PCBs in rats receiving multiple doses
for six weeks. The pharmacokinetic models de-
veloped for rats were modified to enable extrapola-
tion to the mouse. Model parameters such as tissue
values, flow rates, and gut transport were adjusted
in accordance with animal weight and the predicted
PCB disposition compared to experimental data.
Tissue and excreta concentration-time curves ob-
tained in experimental animals generally agreed
with model predictions. The species independence
of the pharmacokinetic model will be tested in dog
and monkey. Experimental data will be obtained
from a contract with the University of Arizona.
The disposition of two additional PCB isomers
(3,3',5,5'-PCB and 2,2',3,3',6,6'-PCB) was studied
in rat to further examine the influence ofdegree and
position ofchlorination on disposition of PCB. The
4-CB, which does not have adjacent unsubstituted
carbons, was metabolized more slowly than pre-
dicted from the degree of chlorination. The 6-CB,
which has an adjacent unsubstituted carbon, was
metabolized as rapidly as the I-CB previously
studied. The metabolites of various PCBs were
isolated and identified as monohydroxy- and dihy-
droxydiol metabolites. Metabolism of PCBs ap-
pears to be a prerequisite for excretion. PCBs that
are persistent in the body are those isomers that are
slowly metabolized by animals.
The disposition of the major component of
Firemaster BP-6 (2,4,5,2',4',5'-hexabromobi-
phenyl) was studied in rats. The polybrominated
biphenyl appears to have similar pharmacokinetic
properties to the correspondinghexachlorobipheqyl
and the half-life of the hexabromo isomer was
longer than the corresponding hexachlorobiphenyl
isomer. A pharmacokinetic model for hexa-
bromobiphenyl is being developed.
The disposition of Kepone, a halogenated insec-
ticide, was also studied. Kepone was stored primar-
ily in the liver and excreted in the bile. The mea-
sured half-life of 18 days was due primarily to re-
absorption of Kepone from the gut after excretion
in the bile.
Another continuing major effort of the Section is
in examination of pharmacokinetic functions of the
lung with regard to both exogenous and endogenous
chemicals. These studies involve the use ofthe iso-
lated perfused rat, guinea pig, and rabbit lung prep-
arations as research tools. With regard to exoge-
nous chemicals, detailed models have developed for
the dynamic interaction of the perfused lung with
circulating chemicals. With regard to endogenous
chemicals, a pharmacokinetic model was developed
for the prostaglandin detoxification system. From
this model, it was evident that flow rates are impor-
tant in examining transport systems in isolated or-
gans. In general, elucidation of the rates and
mechanisms of lung uptake, storage, and
metabolism of chemicals may allow prediction of
possible toxic interactions between environmental
pollutants and other chemicals, including drugs and
endogenous chemicals such as prostaglandins.
The major effort ofthe year was devoted to mod-
ification of existing perfused lung techniques and
development ofnew methods to examine the uptake
and metabolism of inhaled environmental pol-
lutants. Several environmental carcinogens, e.g.,
benzpyrene, have been selected for study and at-
tempts will be made to correlate the uptake and
metabolism of these chemicals to the development
of lung tumors.
Personnel
Two major personnel shifts took place during the
year. Dr. L. G. Hart (Acting Laboratory Chief)
moved into the position of Assistant to the Scien-
tific Director, NIEHS, about midyear, and Dr.
J. R. Fouts (Scientific Director) assumed the re-
sponsibility of Acting Chief. A group headed by
G.E.R. Hook transferred from the Molecular
Pharmacology and Biochemistry Work Group into
the Laboratory of Environmental Toxicology later
in the year. Other members of the group include
Dr. J. W. Spalding (Research Biologist), Dr. D.
Nadeau (Visiting Fellow), Dr. D. Bell (Guest
Worker), and Ms. L. Gilmore (Biologist).
Additions to the laboratory were: Research
Physiologist, J. B. Pritchard (with Dr. Bend); Re-
search Chemist, L. Lazarus (with Dr. DiAugus-
tine); Research Biologist, J. W. Spalding (trans-
ferred from LET, with Dr. Hook); Staff Fellow,
W. Colburn (with Dr. Eling); Visiting Associates,
A. Wilson (with Dr. Eling), H. Mukhtar, T. El-
mamlouk (with Dr. Bend); Visiting Fellows,
Environmental Health Perspectives 1980. Hernandez, R. Weatherby (with Dr. Bend),
M. Szutowski, C. R. Wolf (with Dr. Philpot);
D. Crutchley, A. Kung (with Dr. Eling). L. Ball
(with Dr. Chhabra), M. Khan (with Dr. DiAugus-
tine),J. Leakey (with Dr. Fouts); NIH Postdoctoral
Fellow, J. Maguire (with Dr. Bend); Intergovern-
mental Personnel Act, G. Neufeld (with Dr. Bend),
D. Bell (with Dr. Hook).
Losses from the Laboratory included: J. Maguire
(NIH Postdoctoral Fellow), M. Szutowski (Visit-
ing Fellow), 0. Hernandez (Visiting Fellow, trans-
ferred to EBCB), M. Reasor (NIH Postdoctoral
Fellow), J. Brittian (technician).
Other Activities
Dr. J. R. Bend: Member, Editorial Advisory
Board for DRUG METABOLISM AND DISPOSITION;
Visiting Scientist, C. V. Whitney Ma-
rine Laboratory, University of Florida, St. Au-
gustine; Trustee, Mount Desert Island Biological
Laboratory, Salsbury Cove, Maine; Member,
Committee on Environmental Pharmacology,
American Society for Pharmacology and Experi-
mental Therapeutics; invited participant in a sym-
posium on Formation of Chemically Reactive
Metabolites As a Cause of Drug Toxicity, spon-
sored by ASPET, New Orleans, La., 1976; invited
partcipant at a conference on Aquatic Pollutants
and Biological Effects with Emphasis on Neoplasia,
sponsored by the New York Academy of Sciences,
Sept. 1976; invited speaker at a symposium on
Status of Predictive Tools in Application to Safety
Evaluation: Present and Future, sponsored by NIH
and NCTR, Little Rock, Ark., 1976; invited
speaker on Metabolic Reactions In Vivo and In
Vitro in conference on Short Term Tests for Car-
cinogenicity, sponsored by Toxicology Forum,
Hunt Valley, Md., Feb. 1977; invited lecturer at the
NATO Workshop on Ecotoxicology, University of
Surrey, Guildford, England, July lI-August 5,
1977; invited speaker at symposium entitled En-
vironmental Pharmacology of Lung, sponsored by
ASPET, Columbus, Ohio, Aug. 1977; presented
seminar entitled Metabolism of Xenobiotics by
Marine Species, Department of Pharmacology,
University of Wisconsin, Dec. 1976.
Dr. R. S. Chhabra: Member of the Library
Committee, NIEHS; invited speaker to Interna-
tional Symposium on Nutrition Drug Interactions,
Ames Iowa, 1976.
Dr. R. P. DiAugiistine: Adjunct assistant profes-
sor, Department of Medicine, Duke University;
invited lecturer at Department of Pathology, Duke
University; member of NIEHS Medical Sciences
Lectures Committee; invited speaker at American
Thoracic Society (Eastern Section), Oct. 1976.
Dr. T. E. Eling: Adjunct assistant professor,
Department of Medicine, Duke University; invited
speaker at Deer Lodge Conference on clinical
pharmacokinetics; invited speaker at Gordon Con-
ference on drug metabolism. Reviewer for DRUG
METABOLISM AND DISPOSITION, LIFE SCIENCES,
CANCER RESEARCH, JOURNAL OF PHARMACOLOGY
AND EXPERIMENTAL THERAPEUTICS.
Dr. L. G. Hart: Adjunct associate professor,
Department of Pharmacology, University of North
Carolina, lectures presented to medical and
graduate students of University of North Carolina;
member of NIEHS Safety Committee; NIEHS
project director for coordinating efforts in three
task areas under the "health effects of the non-
nuclear energy technologies" program; associate
managing editor (U.S.A.) for CHEMICO-BIOLOGICAL
INTERACTIONS; editorial board member of
ENVIRONMENTAL HEALTH PERSPECTIVES; chaired
symposium on Pesticides in Aquatic Environments,
15th Congress of Entomology, Washington, D. C.
Dr. G.E.R. Hook: Adjunct assistant professor,
Department of Medicine, Duke University; co-
managing editor and editoral board member of
ENVIRONMENT1AL HEALTH PERSPECTIVES; editoral
board member of CHEMICO-BIOLOGICAL INTER-
ACTIONS.
Dr. R. M. Philpot: Adjunct assistant professor,
Department of Entomology, North Carolina State
University; member of NIEHS editorial board;
editor, CHEMICO-BIOLOGICAL INTERACTIONS.
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